KDL Biotech Ltd Stock Analysis

BSE: 532291 | NSE: KOPDRUGS | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on KDL Biotech

M-Cap below 100cr DeciZen not available

KDL Biotech Price Chart

P/E Ratio (SA):
Market Cap:
5.1 Cr.
52-wk low:
52-wk high:
Bole Toh?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of KDL Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

ROCE % 6.1%5.5%1.8%-24.1%-6.8%-4.8%-14.2%-21.4%-105.3%-129.4%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 20419312410611011356.825.628.426.50
YoY Gr. Rt. %--5.2%-35.9%-14.7%4.4%2.3%-49.7%-55%11%-6.8%-
Adj EPS 2.11.4-1.8-17.2-13.5-5.4-8.5-6-23.4-7.2-5.9
YoY Gr. Rt. %--31.7%-228.6%NANANANANANANA-
BVPS (₹) 35.536.
Adj Net Profit 3.42.4-3-28.9-22.6-9-20.4-14.5-56.3-17.2-14
Cash Flow from Ops. -10.634.914.26.4-1.91.7-
Debt/CF from Ops. -7.2257.9-84.332.2-10.217.738.48.9-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -20.3%-24.9%-22.5%-6.8%
Adj EPS -214.9%NANANA
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 4.12.6-3.3-64.7-31.5-104-104.5-70.2573.93417.6
Op. Profit Mgn %
Net Profit Mgn % 1.71.2-2.4-27.3-20.4-8-35.9-56.5-198.1-65-INF
Debt to Equity
Working Cap Days 1471421821273281292982111661070
Cash Conv. Cycle 626358399022-37-60-56-180

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - KDL Biotech Ltd.

Standalone Consolidated
TTM EPS (₹) -5.9 -
TTM Sales (₹ Cr.) 0 -
BVPS (₹.) -42.5 -
Reserves (₹ Cr.) -126 -
P/BV -0.05 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 2.14 / 2.14
All Time Low / High (₹) 1.61 / 413.35
Market Cap (₹ Cr.) 5.1
Equity (₹ Cr.) 24
Face Value (₹) 10
Industry PE 43.7

Management X-Ray of KDL Biotech :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of KDL Biotech

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


KDL Biotech Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of KDL Biotech on 01-Jan-1970 05:30 is : 0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of KDL Biotech stood at ₹ 5.14.
The latest PE ratio of KDL Biotech as of 01-Jan-1970 05:30 is 0.00.
The latest PB ratio of KDL Biotech as of 01-Jan-1970 05:30 is -0.05
The 52-week high of KDL Biotech is ₹ 2.14 and the 52-week low is ₹ 2.14.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of KDL Biotech is ₹ 0.00 ( Cr.) .

About KDL Biotech Ltd

KDL Biotech, formerly known as Kopran Drugs was incorporated on August 12, 1986 as a private limited company. The bulk drugs division of Kopran at Khopoli was demerged and merged into KDL Biotech with effect from January 1, 1998 pursuant to order u/s 391 to 394 of the Companies Act by the Bombay High Court. The company is a joint venture between Kopran of Parijat Enterprises, India and Synpac Kingdom Pharmaceuticals of Koo Group, Taiwan.

KDL has a biotechnology division, which manufactures Penicillin-G acylase, the enzyme used for conversion of penicillin to 6APA. It has also successfully developed Bleomycin, an anti-cancer drug and a cytoxic antibiotic. The products under development include mitomycin, another anti-cancer drug and Vancomycin, an anti- bacterial.

KDL is one of the largest manufacturers of semi synthetic penicillin in Asia. From a 12 tonne per annum capacity in 1982-83, it expanded to a present capacity of 1200 tonnes per annum. The company's plant is approved by UK MCA, US FDA, South African MCC and several countries with strict compliance of GMP and GLP.


2000 - The union had declared a strike at the company's factory situated at Village Savroli, Taluka Khalapur, Khopoli, District Raigad, Maharashtra. The company's major foray into the business of biotechnology based products it was proposed to change the name of the company from Kopran Drugs to KDL Biotech for which necessary approval was been received from Registrar of Companies, Maharashtra, Mumbai. The company is a major producer of semi-synthetic penicillins (SSP) and the enzyme for converting penicillin-G to 6APA.    

2001- Crisil downgraded the company's NCDs issue to `BB+' from `BBB'.


1. Finished Dosage Forms

• Antibiotics/Antibacterial s• Anti-Malarial • Cadiovasculars • Pain Management • Anthelminthics

2. Active Pharmaceutical Ingredients

• Anti-hypertensives • Macrolides • Taste Masked • Cephalosporins


• Kopran Research Laboratories

Group companies:

• Oriental Containers • United Shippers • Shinrai Toyota • Claridge Moulded Fibre • Kopran


• Gujarat Themis Biosyn • Kampala Pharmaceutical Industries, Uganda

Strategic Business Units:

• Finished Dosage Forms

• Active Pharmaceutical Ingredients

• Research & Development

• Kopran Laboratories

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now